2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations

Area of Science:

• Cardiology
• Atherosclerosis
• Preventive Medicine

Background:

• The 2019 European guidelines introduced significant changes in cardiovascular risk assessment and treatment strategies.
• Previous guidelines may have limited the detection and primary prevention of patients at risk of a first cardiovascular event.

Purpose of the Study:

• To analyze the substantial changes in the 2019 European guidelines for cardiovascular risk assessment and treatment.
• To highlight the need for improved inclusion of risk modifiers, especially for women, in cardiovascular risk stratification.
• To discuss the implementation of PCSK9 inhibitors and new low-density lipoprotein cholesterol goals for very high-risk individuals.

Main Methods:

• Review of the 2019 European Society of Cardiology and European Atherosclerosis Society guideline document.
• Analysis of updated high-risk criteria and categories for cardiovascular events.
• Examination of evidence supporting new low-density lipoprotein cholesterol targets and PCSK9 inhibitor use.

Main Results:

• The updated guidelines enhance the detection and primary prevention of patients at risk of a first cardiovascular event.
• New criteria improve the identification of high-risk individuals.
• The guidelines address the use of PCSK9 inhibitors and set new low-density lipoprotein cholesterol goals (e.g., <55 and <40 mg/dL) for very high-risk patients.

Conclusions:

• The 2019 guidelines represent a significant advancement in cardiovascular risk management.
• Further research and guideline refinement are necessary to incorporate specific risk modifiers for women.
• The guidelines provide a framework for utilizing PCSK9 inhibitors and achieving lower LDL-C targets in high-risk populations.